Visnagin

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Visnagin 具有急性低血压、抗炎和神经保护作用，它通过调节线粒体苹果酸脱氢酶来预防阿霉素诱导的心肌病。

Visnagin has acute hypotensive anti-inflammatory and neuroprotective effects it protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase.

Visnagin (10 μM; for 4, 8, 16, 24 h) induces CYP1A1 transcription in HepG2 cells. Visnagin (10 μM; for 16 h) elevates CYP1B1 gene expression in an aryl hydrocarbon receptor (AHR)-dependent manner, whereas MNF (3’-methoxy-4’-nitroflavone; 20 μM; pre-treated for 1 h) successfully counteracted this induction. Visnagin also enhances PAI-2 transcription in an AHR-dependent manner.

Visnagin (10, 30, 60 mg/kg; ip; for 7 days) is effective in reducing plasma amylase and lipase levels and reduces Cerulein (50 μg/kg, six, hourly i.p. injections) induced oxidative stress in male Swiss albino mice (age: 6-8 weeks, weighing 20-25 g).Visnagin dose dependently decreases the expression of IL-1β, IL-6, TNF-α and IL-17. It attenuates the levels of nuclear p65-NFκB. Visnagin improves the antioxidant defence by improving Nrf2 expression and halts pancreatic inflammation by suppressing NFκB and nitrotyrosine expression in the acinar cells.

——

Others

Other Targets

Others

——

——

82-57-5

230.22

C13H10O4

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (217.18 mM)

CC(Oc1cc(occ2)c2c(OC)c11)=CC1=O

——

(-20℃)

With Ice Pack

≥ 2 years